Fresenius Medical Care AG (FMCQF) Research & Development (2009 - 2026)

Fresenius Medical Care AG has reported Research & Development for 18 years, with the latest figure at $46.1 million in Q2 2026.

• On a quarterly basis, Research & Development rose 6.76% year-over-year to $46.1 million in Q2 2026; TTM through Jun 2026 was $180.4 million, a 3.14% decrease from a year earlier, with the FY2025 full-year figure at $183.9 million, down 6.22% from the prior year.
• Research & Development was $46.1 million for Q2 2026 at Fresenius Medical Care AG, up from $44.9 million in the prior quarter.
• The five-year high for Research & Development was $71.0 million in Q4 2023, with the low at $43.1 million in Q2 2025.
• Average Research & Development over 5 years is $53.3 million, with a median of $52.7 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Research & Development increased 12.26% in 2023, then declined 24.76% in 2024.
• Over 5 years, Research & Development stood at $63.3 million in 2022, then grew by 12.26% to $71.0 million in 2023, then dropped by 24.76% to $53.4 million in 2024, then retreated by 15.03% to $45.4 million in 2025, then advanced by 1.47% to $46.1 million in 2026.
• The last three Research & Development figures came in at $46.1 million (Q2 2026), $44.9 million (Q1 2026), and $45.4 million (Q4 2025), per Business Quant data.